View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 2, 2020updated 02 Mar 2021 5:52pm

Israeli researchers near Covid-19 vaccine development

Scientists at MIGAL Research Institute in Israel expect to start producing a Covid-19 vaccine in the next eight-ten weeks, based on their avian coronavirus Infectious Bronchitis Virus (IBV) vaccine.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

See the full list of coronavirus vaccines/drugs under development

Check the latest vaccination developments with our Covid-19 Vaccine tracker

Scientists at MIGAL Research Institute in Israel expect to start producing a Covid-19 vaccine in the next eight-ten weeks, based on their avian coronavirus Infectious Bronchitis Virus (IBV) vaccine.

The team developed the IBV vaccine after four years of research, funded by the country’s Ministry of Science & Technology and conducted in alliance with the Ministry of Agriculture.

IBV is a disease affecting poultry, and the new vaccine was found to be effective in pre-clinical trials at the Volcani Institute.

The researchers discovered a potential Covid-19 vaccine candidate as a by-product of the IBV vaccine. They made genetic alterations to adapt the IBV vaccine to the human strain of the novel coronavirus.

According to research findings, the poultry coronavirus possesses high genetic similarity to Covid-19 and uses the same mechanism for infection.

Currently, the team is working towards approvals for in-vivo testing and the initiation of manufacturing.

MIGAL Galilee Research Institute CEO David Zigdon said: “Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development. Our goal is to produce the vaccine during the next eight to ten weeks and to achieve safety approval in 90 days.

“This will be an oral vaccine, making it particularly accessible to the general public. We are currently in intensive discussions with potential partners that can help accelerate the in-human trials phase and expedite the completion of final product development and regulatory activities.”

MIGAL Biotechnology Group leader Dr Chen Katz notes that the vaccine’s scientific framework comes from a new protein expression vector.

The vector forms and generates a chimeric soluble protein, which delivers the viral antigen into mucosal tissues via self-activated endocytosis. This stimulates the body to form antibodies against the virus.

In preclinical studies, oral vaccination was found to trigger high levels of specific anti-IBV antibodies.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology